Herceptin

E46088

Herceptin is a targeted monoclonal antibody drug used primarily to treat HER2-positive breast cancer by blocking the HER2 receptor on cancer cells.

All labels observed (5)

Label Occurrences
trastuzumab 8
Herceptin canonical 3
trastuzumab-dkst 1

How this entity was disambiguated

Statements (49)

Predicate Object
instanceOf antineoplastic agent
biologic drug
monoclonal antibody
targeted therapy
antibodyIsotype IgG1
antibodyTarget ERBB2
bindsTo human epidermal growth factor receptor 2
linked to: ERBB2
boxedWarningFor cardiac toxicity
embryo-fetal toxicity
FDAApprovalYear 1998
hasATCCode L01FD01
hasBiosimilar trastuzumab-dkst
linked to: Herceptin

trastuzumab-dttb
trastuzumab-pkrb
linked to: Herceptin

trastuzumab-qyyp
linked to: Herceptin
hasCASNumber 180288-69-1
hasDrugClass HER2 inhibitor
antibody-based therapy
hasGenericName trastuzumab
linked to: Herceptin
hasMolecularType humanized monoclonal antibody
hasUNII P188ANX8CK
isAdministeredAs weight-based dosing
isContraindicatedWith severe hypersensitivity to trastuzumab
isIndicatedAs adjuvant therapy
neoadjuvant therapy
isIndicatedInCombinationWith carboplatin
docetaxel
paclitaxel
pertuzumab
isListedOn World Health Organization Model List of Essential Medicines
isMarketedBy Roche
isProducedBy Genentech
isUsedFor HER2-positive breast cancer
HER2-positive gastric cancer
HER2-positive gastroesophageal junction adenocarcinoma
early-stage HER2-positive breast cancer
metastatic HER2-positive breast cancer
mechanismOfAction induces antibody-dependent cell-mediated cytotoxicity
inhibits HER2-mediated signaling pathways
prevents HER2 receptor dimerization
requiresTestingFor HER2 gene amplification
HER2 overexpression
routeOfAdministration intravenous infusion
seriousAdverseEffect cardiomyopathy
congestive heart failure
infusion-related reactions
pulmonary toxicity
targets HER2 receptor
wasApprovedBy U.S. Food and Drug Administration

How these facts were elicited

Referenced by (14)

Full triples — surface form annotated when it differs from this entity's canonical label.

Genentech notableProduct Herceptin
Roche product Herceptin
Herceptin hasGenericName trastuzumab
linked to: Herceptin
Herceptin hasBiosimilar trastuzumab-dkst
linked to: Herceptin
Herceptin hasBiosimilar trastuzumab-pkrb
linked to: Herceptin
Herceptin hasBiosimilar trastuzumab-qyyp
linked to: Herceptin
Perjeta usedInCombinationWith trastuzumab
linked to: Herceptin
HER2 receptor targetOfDrug trastuzumab
linked to: Herceptin
ERBB2 therapeuticTargetOf trastuzumab
linked to: Herceptin
CLEOPATRA trial intervention trastuzumab
linked to: Herceptin
CLEOPATRA trial drugEvaluated trastuzumab
linked to: Herceptin
APHINITY trial evaluatedDrug trastuzumab
linked to: Herceptin
APHINITY trial coDeveloperDrug Herceptin
pertuzumab oftenUsedWith trastuzumab
linked to: Herceptin